- Home
- CANF vs ABTS Comparison
CANF vs ABTS Comparison
Compare CANF & ABTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- ABTS
- Stock Information
- Founded
- CANF 1994
- ABTS 2010
- Country
- CANF Israel
- ABTS Hong Kong
- Employees
- CANF N/A
- ABTS N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- ABTS Computer Software: Programming Data Processing
- Sector
- CANF Health Care
- ABTS Technology
- Exchange
- CANF Nasdaq
- ABTS Nasdaq
- Market Cap
- CANF 14.4M
- ABTS 16.0M
- IPO Year
- CANF N/A
- ABTS N/A
- Fundamental
- Price
- CANF $1.52
- ABTS $0.47
- Analyst Decision
- CANF Strong Buy
- ABTS
- Analyst Count
- CANF 2
- ABTS 0
- Target Price
- CANF $14.00
- ABTS N/A
- AVG Volume (30 Days)
- CANF 1.2M
- ABTS 88.5K
- Earning Date
- CANF 02-03-2025
- ABTS 12-31-2024
- Dividend Yield
- CANF N/A
- ABTS N/A
- EPS Growth
- CANF N/A
- ABTS N/A
- EPS
- CANF N/A
- ABTS N/A
- Revenue
- CANF $667,000.00
- ABTS $5,343,888.00
- Revenue This Year
- CANF $409.56
- ABTS N/A
- Revenue Next Year
- CANF N/A
- ABTS N/A
- P/E Ratio
- CANF N/A
- ABTS N/A
- Revenue Growth
- CANF N/A
- ABTS 3970.67
- 52 Week Low
- CANF $1.29
- ABTS $0.38
- 52 Week High
- CANF $4.69
- ABTS $1.60
- Technical
- Relative Strength Index (RSI)
- CANF 41.02
- ABTS 40.24
- Support Level
- CANF $1.41
- ABTS $0.43
- Resistance Level
- CANF $1.54
- ABTS $0.49
- Average True Range (ATR)
- CANF 0.10
- ABTS 0.06
- MACD
- CANF 0.02
- ABTS -0.01
- Stochastic Oscillator
- CANF 52.38
- ABTS 12.81
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations.